Search Results
Your search for The ASCO Post Staff,The ASCO Post Staff matches 6160 pages
Showing 901 - 950Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy
Investigators have found that patients with breast cancer who have insufficient levels of vitamin D prior to initiating treatment with paclitaxel may be more likely to experience peripheral neuropathy, according to a recent study published by Chen et al in JNCCN–Journal of the National...
FDA Approves First Treatment for Patients With Rare Congenital Blood Disorder
On November 9, the U.S. Food and Drug Administration (FDA) approved ADAMTS13, recombinant-krhn (Adzynma), the first genetically engineered protein product indicated for prophylactic or on-demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic...
FDA Amends Pembrolizumab’s Gastric Cancer Indication
On November 7, the U.S. Food and Drug Administration (FDA) revised the existing indication of pembrolizumab (Keytruda) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer
On November 8, the U.S. Food and Drug Administration (FDA) approved fruquintinib (Fruzaqla) for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF therapy; and—if their disease is RAS wild-type and it...
British Pharmacological Society Names V. Craig Jordan, DSc, PhD, Recipient of the Sir Henry Wellcome Gold Medal
In December 2023, the British Pharmacological Society will present the Sir Henry Wellcome Gold Medal to Prof. V. Craig Jordan, CMG, OBE, DSc, PhD, FMedSci, FBPhS. This is the highest award for lifetime contributions to pharmacology by the British Pharmacological Society of Great Britain. Dr. Jordan ...
Genetics of Nearby Healthy Tissue May Help Predict Lung Cancer Recurrence
Genetic information collected from healthy tissue near lung tumors may be predictive of posttreatment cancer recurrence compared with analysis of the tumors themselves, according to a novel study published by Dolgalev et al in Nature Communications. Background Lung adenocarcinomas are tumors that...
Computer Models May Help Reduce Cancer Disparities
Sophisticated computer models may help reduce health disparities in incidence and mortality for patients with major cancer types, according to a collection of new studies published in a special issue of the Journal of the National Cancer Institute. Background Given the high costs and long time...
ASCO Applauds Confirmation of Monica Bertagnolli, MD, FACS, FASCO, as NIH Director
On November 7, the Senate overwhelmingly confirmed Monica M. Bertagnolli, MD, FACS, FASCO, by a vote of 62 to 36, as the 17th Director of the National Institutes of Health (NIH). Dr. Bertagnolli is currently Director of the National Cancer Institute (NCI). She served as ASCO President from 2018 to ...
Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy
Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and the Ludwig Maximilian University, discusses an interim analysis of the monarchE trial on adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. The data...
Nemtabrutinib May Provide Benefit in Patients With Relapsed Hematologic Malignancies
The BTK inhibitor nemtabrutinib may offer a new treatment option for patients with relapsed hematologic malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, according to a recent study published by Woyach et al in Cancer Discovery. Background Hematologic malignancies are...
Low-Dose CT Screenings Leading to Early Diagnosis May Improve Long-Term Lung Cancer Survival Rates
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...
Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy
Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in...
Race, PSA Level, and Risk of Prostate Cancer
Black men in the United States are more likely to develop prostate cancer than White men, and after diagnosis, they’re more likely to have advanced disease and to die of the disease than White men. Although it would seem that earlier prostate‐specific antigen (PSA) screening would reduce the risk...
Mark M. Awad, MD, PhD, on NSCLC: Neoadjuvant Nivolumab Plus Ipilimumab vs Chemotherapy
Mark M. Awad, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings from the CheckMate 816 trial, which showed a potential clinical benefit to neoadjuvant nivolumab plus ipilimumab vs chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) (Abstract 1261O).
Can High BMI in Youth Affect Cancer Risk Later On?
Men with overweight or obesity at age 18 years may have a higher risk of 17 different cancers later in life, according to recent research from the University of Gothenburg. The findings also describe how the youth obesity epidemic is expected to affect cancer incidence over the next 30 years. In...
Machine-Learning Model May Accurately Calculate Chemotherapy Success in Patients With Osteosarcoma
Researchers have developed and trained a new machine learning model to calculate percent necrosis in patients with osteosarcoma, according to a novel study published by LiBrizzi et al in the Journal of Orthopaedic Research. Background A postchemotherapy percent necrosis calculation often helps...
Novel Strategy May Improve Outcomes in Patients With Treatment-Resistant DLBCL
Researchers have found that a DNA repair–facilitating mechanism may be responsible for a tumor’s treatment resistance and could be treated with a combination of chemotherapies, according to a recent study published by Marullo et al in Cancer Research. The mechanism involves the shuttling of...
Secondary PIK3CA Mutations, Drug Resistance, and Novel PI3K Alpha Inhibitors in Breast Cancer
Researchers have discovered that resistance to PI3K-alpha inhibitors and reduced drug binding in patients with breast cancer may be driven by secondary PIK3CA mutations and so may be effectively treated with a novel class of PI3K-alpha inhibitors designed to bind to different parts of the target,...
Personalized Care May Prevent Overscreening for Colorectal Cancer in Older Patients
Researchers have found that presenting older patients with personalized information regarding the benefits and harms of colorectal cancer screenings may reduce unnecessary screenings, according to a recent study published by Saini et al in JAMA Internal Medicine. Background Colorectal cancer...
2023 National Youth Tobacco Survey Shows Drop in E-Cigarette Use Among High School Students
On November 2, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released data from the 2023 National Youth Tobacco Survey (NYTS) on tobacco product use among U.S. youth. The findings—which were collected between March and June 2023 and were...
Novel Blood Test May Offer Early Cancer Detection
Researchers have developed a highly sensitive blood test capable of early detection by identifying a key protein produced by cancer cells, according to a novel study published by Taylor et al in Cancer Discovery. Background Many tumors become deadly by remaining asymptomatic until they’re too...
Immune Checkpoint Inhibition With Single-Fraction Stereotactic Radiosurgery May Not Increase Risk of Radiation Necrosis in Patients With NSCLC Brain Metastases
Researchers have explored the impact of immune checkpoint inhibition and single-fraction stereotactic radiosurgery on radiation necrosis in patients with non–small cell lung cancer (NSCLC) brain metastases, according to a novel study published by Lehrer et al in the Journal of Neuro-Oncology. Study ...
International Group of Surgical Oncologists Presents New Commission Outlining Pragmatic Solutions to Improve Cancer Surgery Outcomes Worldwide
Building upon recommendations from the 2015 Lancet Oncology Global Cancer Surgery Commission, a new Commission report aims to provide a pragmatic roadmap for decision-makers to reduce inequities and promote safe, timely, and affordable cancer surgery for every patient. The Commission report was...
FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer
On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966 Efficacy was evaluated in KEYNOTE-966...
Hossein Borghaei, DO, on Nonsquamous NSCLC: Findings on Sitravatinib Plus Nivolumab vs Docetaxel
Hossein Borghaei, DO, of Fox Chase Cancer Center, discusses phase III findings from the SAPPHIRE study of sitravatinib plus nivolumab vs docetaxel in patients with previously treated, advanced nonsquamous non–small cell lung cancer (NSCLC) (Abstract LBA63).
Insurance Coverage Disruptions May Reduce Rate of Cancer Screenings
Investigators have found that U.S. adult patients with prior insurance coverage disruptions may be less likely to receive guideline-concordant and past-year cancer screenings compared with those with continuous coverage, according to new findings presented by Shi et al at the 2023 ASCO Quality Care ...
Expanded Soy Production in Brazil May Be Linked to Increased Mortality Among Pediatric Patients With ALL
Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased risk of mortality among pediatric patients with acute lymphoblastic leukemia (ALL). The study was published by Skidmore et al in...
Ze-rui Zhao, PhD, on Resectable NSCLC: SBRT With Sequential Immunochemotherapy
Ze-rui Zhao, PhD, of China’s Sun Yat-sen University Cancer Center, discusses new phase II findings on stereotactic body radiation therapy (SBRT) with sequential immunochemotherapy as a neoadjuvant treatment of patients with resectable non–small cell lung cancer (NSCLC). This therapy yielded a high...
Patients With Newly Diagnosed NSCLC or Melanoma May Receive Limited Documentation of Treatment Cost Discussions
Investigators have uncovered that only about 25% of patients newly diagnosed with advanced cancer have documented physician discussions about the costs of care, which may make it more difficult to identify patient needs and track the outcomes of referrals for assistance, according to new findings...
Role of Crowdfunding Campaigns in Covering Medical Expenses for Cancer Survivors
Investigators have discovered that cancer survivors in the United States may be increasingly utilizing crowdfunding campaigns like GoFundMe to help cover the costs of medical and other basic household expenses, according to new findings presented by Zheng et al and Yu et al at the 2023 ASCO Quality ...
Jonathan D. Spicer, MD, PhD, on Early-Stage NSCLC: Survival Results With Pembrolizumab
Jonathan D. Spicer, MD, PhD, of McGill University, discusses findings from the KEYNOTE-671 study of perioperative pembrolizumab for patients with resectable early-stage non–small cell lung cancer (NSCLC). Neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab...
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
On October 27, the U.S. Food and Drug Administration (FDA) approved toripalimab-tpzi (Loqtorz) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for...
Two New Studies Using CancerLinQ Data
Two new studies—presented by Drumheller et al and Vento et al at the 2023 ASCO Quality Care Symposium—utilized data from ASCO’s CancerLinQ® database (Abstracts 418 and 532). One study revealed deficiencies in biomarker testing and tracking in electronic health records, and the other analyzed...
Datopotamab Deruxtecan May Improve Progression-Free Survival in Patients With Metastatic NSCLC
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan may significantly improve progression-free survival in patients with metastatic non–small cell lung cancer (NSCLC), especially in patients with non–squamous cell tumors, according to new findings simultaneously published by Ahn et...
PFAS Exposure May Increase Risk of Thyroid Cancer
Researchers may have discovered a link between certain per- and polyfluoroalkyl substances (PFAS)—also referred to as "forever chemicals"—and an increased risk of thyroid cancer, according to a recent study published by van Gerwen et al in eBioMedicine. Background PFAS are a large, complex group of ...
Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy
Researchers have found that a text message–based program in combination with routine laboratory testing could safely accelerate patients to treatment with immune checkpoint inhibitors, eliminate the need for in-person assessments with their physicians, and save them about 1.5 hours in total wait...
Yoga-Based Supportive Care May Prevent Treatment-Related Complications in Patients With Head and Neck Cancer
Yoga-based supportive care may help alleviate the negative side effects of radiation treatment, decrease the use of feeding tube placements, and reduce emergency department visits in patients with head and neck cancer, especially when family caregivers participate, according to new findings...
Mind-Body Fitness Classes May Reduce Unplanned Hospitalizations, Urgent Care Visits During Cancer Care
Participation in virtual mind-body fitness classes may be effective at reducing hospitalizations, urgent care visits, and the length of hospital stays among patients with cancer by about 50%, according to new findings presented by Mao et al at the 2023 ASCO Quality Care Symposium (Abstract 473)....
FDA Approves Ivosidenib for Myelodysplastic Syndromes
On October 24, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test. The FDA also approved the...
Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
University of Arizona Welcomes Thoracic Surgeon Praveen Sridhar, MD
The University of Arizona College of Medicine–Tucson Department of Surgery is pleased to welcome Praveen Sridhar, MD, as Clinical Associate Professor in the Department of Surgery’s Division of Cardiothoracic Surgery. Dr. Sridhar, who is particularly interested in thoracic oncology and minimally...
Breakthrough Prize, ‘Oscars of Science,’ Celebrates 2024 Laureates in Life Sciences
On September 14, 2023, the Breakthrough Prize Foundation announced the winners of the 2024 awards, honoring an esteemed group of the world’s researchers for their impactful scientific discoveries, including a subset responsible for substantial progress in the understanding and treatment of major...
Patient Education Materials on Breast Cancer May Be Difficult to Access
Investigators have discovered that reliable educational materials about breast cancer surgery may be difficult to access and are often presented at much higher reading levels than recommended, according to the findings of two new studies presented by Brennan et al and Satarasinghe et al at the...
AI-Based Calculator May Accurately Predict Long-Term Cancer Survival
Researchers have developed a novel artificial intelligence (AI)-based Cancer Survival Calculator for estimating long-term survival in patients with newly diagnosed cancer, according to new findings presented by Janczewski et al at the American College of Surgeons (ACS) Clinical Congress 2023....
Novel Strategies for Eliminating Dormant Tumor Cells in Breast Cancer Survivors
Researchers have discovered that it may be possible to detect and treat dormant tumor cells in breast cancer survivors, according to new findings presented by DeMichele et al at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract 244MO). The results may have offered a...
PSMAfore: Lutetium Lu-177 Vipivotide Tetraxetan in Metastatic Prostate Cancer
Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...
Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other results of...
Induction Chemotherapy and Subsequent Chemoradiation May Improve Survival and Recurrence Rates in Patients With Cervical Cancer
Researchers have found that a short course of induction chemotherapy prior to chemoradiation may be effective at reducing the rate of relapse and mortality among patients with locally advanced cervical cancer, according to new preliminary findings presented by McCormack et al at the European...
Nivolumab Plus Gemcitabine and Cisplatin May Improve Survival in Patients With Metastatic Urothelial Carcinoma
Researchers have found that nivolumab in combination with a chemotherapy regimen may improve the rate of survival in patients with metastatic urothelial carcinoma, according to new findings simultaneously published by van der Heijden et al in The New England Journal of Medicine and presented at the ...
Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial
The Alliance for Clinical Trials in Oncology announced detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors. The data were presented by Chan et al at the...
